CC
RGLS

Callan Capital’s Regulus Therapeutics RGLS Stock Holding History

Callan Capital’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-238
Closed -$198K – 71
2016
Q1 		$198K Hold
238
– – 0.08% 57
2015
Q4 		$250K Sell
238
-31
-12% -$31.1K 0.1% 55
2015
Q3 		$211K Hold
269
– – 0.11% 58
2015
Q2 		$354K Buy
+269
New +$434K 0.07% 58
2015
Q1 		– Sell
-667
Closed -$1.28M – 72
2014
Q4 		$1.28M Hold
667
– – 0.29% 43
2014
Q3 		$546K Hold
667
– – 0.15% 46
2014
Q2 		$643K Sell
667
-4
-0.6% -$3.43K 0.17% 44
2014
Q1 		$726K Buy
671
+218
+48% +$242K 0.24% 37
2013
Q4 		$402K Buy
+453
New +$390K 0.15% 37

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Callan Capital's RGLS Position: Q2 2016 in Review

Callan Capital sold out of Regulus Therapeutics (RGLS) in Q2 2016, closing a stake of 238 shares — an estimated $198K sold.

Callan Capital first reported a position in RGLS in Q4 2013 and held it in 9 quarters. The position peaked at $1.28M in Q4 2014. 83 funds tracked by Wall St. Rank hold RGLS as of Q2 2016.

  • Callan Capital reported no remaining Regulus Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Callan Capital sold 238 Regulus Therapeutics shares in Q2 2016, an estimated $198K.
  • Callan Capital first reported a position in Regulus Therapeutics in Q4 2013 and held it in 9 quarters.
  • Callan Capital's Regulus Therapeutics position peaked at $1.28M in Q4 2014.
  • 83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2016.

Based on Callan Capital's 13F filing for Q2 2016, filed 12 Aug 2016.